Anti-NMDA receptor Encephalitis

Smooth ER: Renata Daniels, Emma Worden-Sapper

Background

- Auto-immune disorder
- 81% of cases affect women
- Median age of diagnosis is 21 years
- Associated with ovarian teratomas
- 75 % diagnosed recover, mortality rate is 7 % (according to a 2008 study)
- Categorized and named by Joseph Dalmau, 2007
- Symptoms mimic described characteristics of demonic possession
- Commonly undiagnosed or misdiagnosed, e.g. as bipolar disorder





Prodromal

- Headaches
- Flu-like symptoms
- Fatigue
- Fever

"When he suggested I try to relax, I turned to face him, staring past him like I was possessed. My arms suddenly whipped straight out in front of me, like a mummy, as my eyes rolled back and my body stiffened. I was gasping for air... Blood and foam began to spurt out of my mouth through clenched teeth... I would never regain any memories of this seizure, or the ones to come." - Susannah Cahalan, Brain on Fire

Progression

- Paranoia
- Psychosis
- Seizure
- Cerebellar ataxia
- Memory deficits
- Speech problems (aphasia, perseveration, mutism)
- Motor symptoms
- Hemiparesis
- Hypoventilation
- Delusions and/or hallucination
- Catatonia

Diagnosis

- Psychological, cognitive tests
- Anti-NMDAR antibody cerebral spinal fluid (CSF) analysis
- MRI scan for lesions (cortex, basal ganglia, thalamus)
- Brain biopsy







Specific functionality

- Glutamatergic
- lonotropic
- Na+ and Ca++ permeable
- Excitatory response
- Magnesium plug is removed when the membrane is depolarized
- Glycine is a co-agonist
- Heterotetramer (two NR1 subunits, two NR2 subunits)

Brain functionality

- Synaptic plasticity
- Calcium can function as a second messenger after an action potential
- Memory formation, learning, synaptogenesis

NMDA receptor localization



Proposed Mechanisms of Action

1. BBB damage

- a. Acute inflammation
- b. CRH and mast cell interaction
- c. Autonomic dysfunction (i.e. increased blood pressure)
- 2. Intrathecal antibody production
- 3. Excessive levels of antibodies in the CSF induce degradation of NMDAR GluN1 subunit
 - a. NMDAR cross-linkage
 - b. Direct antagonism of NMDAR
 - c. Complement cascade



NMDAR cross-linkage

- A. Localization of AMPA and NMDA receptors at PSD
- B. Selective binding of antibodies to NMDAR and receptor cross-linking
- C. Internalization of antibody-bound NMDAR
- D. Cultured rodent neurons treated with control CSF and stained for NR1, VGlut, and PSD-95
- E. Patient CSF treatment
- F. CSF control of mEPSC dependent on NMDAR
- G. Patient CSF

Moscato et al., 2010

Genetic Factors

HLAI-allele B*07:02

- Encodes MHC class I peptides

 Identifies non-self
 peptides to antigen presenting cells
 - Expressed in phagocytes,
 B cells, and others



Treatments

1. First-line immunotherapy (steroids, immunoglobulin, plasmapheresis, immunoadsorption) + removal of teratoma (if present)

2. Second-line immunotherapy: Rituximab, alemtuzumab (experimental)

3. Transcranial direct current stimulation as a treatment for associated cognitive disorders

4. Effectiveness of treatments varies from patient to patient



Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis (IANMDAR)

Cohort: 20, Intervention: Immunoadsorption therapy in conjunction with Rituximab

Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis

Cohort: 40, Intervention: Transcranial Direct Current Stimulation

Future Directions



Left: Potential binding pockets on the NR1 subunit of the NMDA receptor

Spreading awareness of the disease

Determine the mechanism of action, genetic factors



Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: A retrospective study. (2013, December 18). Retrieved from

https://www.sciencedirect.com/science/article/pii/S1474442213702825?via=ihub

Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., . . . Lynch, D. R. (2008, December). Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607118/

Dowben, J. S., Kowalski, P. C., & Keltner, N. L. (2015). Biological Perspectives. Perspectives in Psychiatric Care, 51(4), 236-240. doi:10.1111/ppc.12132

Fauci, A. S. (1983, October). Corticosteroids in autoimmune disease. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/6413383

Gresa-Arribas, N., Titulaer, M. J., Torrents, A., Aguilar, E., McCracken, L., Leypoldt, F., . . . Dalmau, J. (2014, February). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006368/

Hartung, H. P. (2008, July). Advances in the understanding of the mechanism of action of IVIg. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18685919



Hughes, E. G., Peng, X., Gleichman, A. J., Lai, M., Zhou, L., Tsou, R., . . . Balice-Gordon, R. J. (2010, April 28). Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis. Retrieved from

http://www.jneurosci.org/content/30/17/5866

Human leukocyte antigens - Genetics Home Reference. (n.d.). Retrieved from https://ghr.nlm.nih.gov/primer/genefamily/hla

Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis - Full Text View. (n.d.). Retrieved from https://clinicaltrials.gov/ct2/show/NCT03274375?cond=Anti-NMDA Receptor

Encephalitis&rank=2Moscato, E. H., Jain, A., Peng, X., Hughes, E. G., Dalmau, J., & Balice-Gordon, R. J. (2010).

Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: Insights from molecular, cellular and synaptic studies. *European Journal of Neuroscience*, 32(2), 298-309. doi:10.1111/j.1460-9568.2010.07349.x

Mueller, S. H., Färber, A., Prüss, H., Melzer, N., Golombeck, K. S., Kümpfel, T., . . . German, (. G. (2018, April). Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29572931

"Viral Encephalitis." n.d. Accessed April 26, 2018. http://neuropathology-web.org/chapter5/chapter5dViruses.html.

Zentrum für Bioinformatik: Universität Hamburg - Proteins ... (n.d.). Retrieved from

D3mfuPi22JO4dl0UQChw&v=1&r=https://proteins.plus/&p=DevEx.LB.1,5493.1